vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and VinFast Auto Ltd. (VFS). Click either name above to swap in a different company.
VinFast Auto Ltd. is the larger business by last-quarter revenue ($718.6M vs $699.9M, roughly 1.0× QuidelOrtho Corp). VinFast Auto Ltd. runs the higher net margin — -2.8% vs -104.7%, a 101.9% gap on every dollar of revenue.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
VinFast Auto Ltd. is a Vietnamese multinational automotive company founded by Vingroup, one of the largest private conglomerates in Vietnam that was founded by Phạm Nhật Vượng.
QDEL vs VFS — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $718.6M |
| Net Profit | $-733.0M | $-20.0M |
| Gross Margin | — | — |
| Operating Margin | -100.7% | -96.1% |
| Net Margin | -104.7% | -2.8% |
| Revenue YoY | -3.7% | — |
| Net Profit YoY | -3583.4% | — |
| EPS (diluted) | $-10.78 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $699.9M | $718.6M | ||
| Q2 25 | $613.9M | $663.0M | ||
| Q1 25 | $692.8M | $656.5M | ||
| Q4 24 | $707.8M | — | ||
| Q3 24 | $727.1M | $511.6M | ||
| Q2 24 | $637.0M | — | ||
| Q1 24 | $711.0M | $302.6M | ||
| Q4 23 | $742.6M | — |
| Q3 25 | $-733.0M | $-20.0M | ||
| Q2 25 | $-255.4M | $-51.8M | ||
| Q1 25 | $-12.7M | $-26.1M | ||
| Q4 24 | $-178.4M | — | ||
| Q3 24 | $-19.9M | $-10.4M | ||
| Q2 24 | $-147.7M | — | ||
| Q1 24 | $-1.7B | $-618.3M | ||
| Q4 23 | $7.0M | — |
| Q3 25 | -100.7% | -96.1% | ||
| Q2 25 | -29.4% | -79.0% | ||
| Q1 25 | 4.7% | -74.0% | ||
| Q4 24 | -14.2% | — | ||
| Q3 24 | 2.1% | -65.9% | ||
| Q2 24 | -18.4% | — | ||
| Q1 24 | -247.3% | -139.4% | ||
| Q4 23 | 5.4% | — |
| Q3 25 | -104.7% | -2.8% | ||
| Q2 25 | -41.6% | -7.8% | ||
| Q1 25 | -1.8% | -4.0% | ||
| Q4 24 | -25.2% | — | ||
| Q3 24 | -2.7% | -2.0% | ||
| Q2 24 | -23.2% | — | ||
| Q1 24 | -239.9% | -204.3% | ||
| Q4 23 | 0.9% | — |
| Q3 25 | $-10.78 | — | ||
| Q2 25 | $-3.77 | — | ||
| Q1 25 | $-0.19 | — | ||
| Q4 24 | $-2.54 | — | ||
| Q3 24 | $-0.30 | — | ||
| Q2 24 | $-2.20 | — | ||
| Q1 24 | $-25.50 | — | ||
| Q4 23 | $0.11 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $8.8M |
| Total DebtLower is stronger | $2.5B | — |
| Stockholders' EquityBook value | $2.0B | — |
| Total Assets | $5.7B | $183.2M |
| Debt / EquityLower = less leverage | 1.23× | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $98.1M | $8.8M | ||
| Q2 25 | $151.7M | $650.0M | ||
| Q1 25 | $127.1M | $2.4M | ||
| Q4 24 | $98.3M | — | ||
| Q3 24 | $143.7M | $1.9M | ||
| Q2 24 | $107.0M | — | ||
| Q1 24 | $78.5M | $3.0M | ||
| Q4 23 | $167.3M | — |
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.1B | — | ||
| Q1 25 | $2.1B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — | ||
| Q1 24 | $2.2B | — | ||
| Q4 23 | $2.3B | — |
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.8B | $-7.2B | ||
| Q1 25 | $3.0B | — | ||
| Q4 24 | $3.0B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — | ||
| Q1 24 | $3.3B | — | ||
| Q4 23 | $5.0B | — |
| Q3 25 | $5.7B | $183.2M | ||
| Q2 25 | $6.4B | $7.2B | ||
| Q1 25 | $6.5B | $158.2M | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.8B | $151.8M | ||
| Q2 24 | $6.7B | — | ||
| Q1 24 | $6.7B | $145.6M | ||
| Q4 23 | $8.6B | — |
| Q3 25 | 1.23× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.70× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.68× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.68× | — | ||
| Q4 23 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | — |
| Free Cash FlowOCF − Capex | $-94.7M | — |
| FCF MarginFCF / Revenue | -13.5% | — |
| Capex IntensityCapex / Revenue | 7.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-45.5M | — | ||
| Q2 25 | $-46.8M | — | ||
| Q1 25 | $65.6M | — | ||
| Q4 24 | $63.7M | — | ||
| Q3 24 | $117.9M | — | ||
| Q2 24 | $-97.9M | — | ||
| Q1 24 | $-700.0K | — | ||
| Q4 23 | $80.4M | — |
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | — | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — | ||
| Q4 23 | $31.8M | — |
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — | ||
| Q4 23 | 4.3% | — |
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — | ||
| Q4 23 | 6.5% | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | 11.49× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
VFS
| Sales of vehicles | $662.9M | 92% |
| Sales of spare parts and components | $41.3M | 6% |
| Revenue from leasing activities | $12.3M | 2% |
| Finance income | $2.4M | 0% |
| Rendering of services | $1.2M | 0% |
